


Table of contents



Alcohol Withdrawal

Registrar Education Series

Updated February 2023

HARM
REDUCTION
~~MEANS~~

Saved my
life.

 harm reduction
coalition

Quick reference

Table of contents



Background

Treatment basics

Screening

Benzodiazepines

Treatment settings

Harm reduction



Quick reference

CIWA-Ar

Benzodiazepine option 2

PAWSS

Benzodiazepine option 3

Inpatient treatment

Naltrexone

Benzodiazepine option 1

Acamprosate



Background?


What percentage of people with alcohol use disorder who abruptly stop drinking will experience withdrawal symptoms?

How early do signs of withdrawal begin and how does it evolve?



Background

Alcohol Withdrawal Timeline



½ of people with [AUD](#) who abruptly reduce or abstain from alcohol will experience symptoms of withdrawal

Withdrawal begins within 6-24 hours

6-12 hours: anorexia, diaphoresis, GI upset, headache, insomnia, mild anxiety, palpitations, tremulousness

12-24 hours: alcoholic hallucinosis: auditory, tactile or visual hallucinations

12-48 hours withdrawal seizures (50% will progress to DTs)

48 hours – 5 days Delirium tremens



Screening?

What screening tools are used to detect alcohol use disorder?

What is considered risky drinking?

How is alcohol withdrawal classified/scored?

What are the treatment goals when caring for someone experiencing withdrawal?



Screening

Screen for *alcohol use disorder* with [AUDIT-C](#), SASQ, if positive than do the full AUDIT

Risky drinking

Men: Drinking ≥ 5 drinks on one occasion or ≥ 15 per week


Women and men > 65yo: Drinking 4 or more drinks on one occasion or more than 7 per week


Alcohol withdrawal is classified as [Mild](#), [Moderate](#), [Severe](#) and complicated (seizures or delirium)

Provider scored [CIWA-Ar](#), [PAWSS](#)

Patient scored SAWS

Treatment goals: Lower mortality, prevent seizures and prevent progression to delirium tremens and reduce withdrawal symptoms





Alcohol Use Disorder – DSM V



- Alcohol is often taken in larger amounts or over a longer period than was intended.
- There is a persistent desire or unsuccessful efforts to cut down or control alcohol use.
- A great deal of time is spent in activities necessary to obtain alcohol, use alcohol, or recover from its effects.
- Craving, or a strong desire or urge to use alcohol.
- Recurrent alcohol use resulting in a failure to fulfill major role obligations at work, school, or home.
- Continued alcohol use despite having persistent or recurrent social or interpersonal problems caused or exacerbated by the effects of alcohol.
- Important social, occupational, or recreational activities are given up or reduced because of alcohol use.
- Recurrent alcohol use in situations in which it is physically hazardous.
- Alcohol use is continued despite knowledge of having a persistent or recurrent physical or psychological problem that is likely to have been caused or exacerbated by alcohol.
- Tolerance
- Withdrawal



Treatment settings for withdrawal?

What are different options for treating settings?

What patient characteristics are optimal for each setting?



Treatment settings

- **Outpatient**
 - Mild symptoms and otherwise medically and psychiatrically stable
 - Daily follow up for up to 5 days after last drink.
 - Evaluate symptom severity, overall health, mental status, hydration, sleep, mood, suicidality and substance use
- **Level 2 Outpatient**
 - extended on-site monitoring
 - moderate symptoms with a risk of complicated withdrawal
- **In-patient**
 - PAWSS ≥ 4 , severe, complicated or additional risk factors



Mild

CIWA-Ar: <10 or SAWS <12 symptoms with minimal risk of developing severe/complicated withdrawal can be treated with supported care with or without pharmacotherapy

Minimal risk (none): history of withdrawal-related delirium or seizures, multiple prior withdrawal episodes comorbid illness, age older than 65 years, long duration of alcohol consumption (e.g., heavy alcohol use five or more days in the past month), seizures during current withdrawal episode, marked autonomic hyperactivity on presentation, and physiologic dependence on GABAergic agents

Supportive care: educating patients on the course of withdrawal, monitoring for severe withdrawal, instructing them on how to maintain low-stimulation home environments, consuming noncaffeinated fluids

Recommend a daily multivitamin containing 400 mcg of folic acid, and prescribe thiamine 100 mg daily for three to five days

Medications

Benzodiazepines (CIWA-Ar ≥ 8)

Carbamazepine (Tegretol)

Gabapentin (Neurontin)



Moderate

CIWA-Ar 10-18 or SAWS >12

Triggered benzodiazepines preferred

Long acting chlordiazepoxide (Librium) and diazepam (Valium) are preferred

If significant liver disease is present lorazepam (Ativan) and oxazepam (Serax) should be used



Severe

CIWA-Ar ≥ 19

Complicated if there are seizures or delirium tremens

Symptom triggered (preferred) benzodiazepines to achieve a calm but alert state for seizure

Cooperative patient can take oral therapy

Agitated or uncooperative patient, unable to tolerate oral will need IV therapy



Withdrawal treatment basics?

What are the basics to in-patient alcohol withdrawal?




Alcohol Withdrawal Treatment Basics

- PAWSS ≥ 4 needs to be admitted inpatient
- Daily multivitamin containing 400 mcg of folic acid
- Thiamine 100 mg daily for three to five days
 - If Wernicke encephalopathy is suspected increase to 500mg IV TID
- Symptom triggered benzodiazepines are preferred in-patient with a CIWA-Ar ≥ 8 to achieve a calm but alert state
 - Long-acting diazepam and chlordiazepoxide are preferred
 - If advanced liver disease, alcoholic hepatitis or >65 yo lorazepam or oxazepam are preferred
- Front loading is preferred in high-risk patients who have a history of seizures or delirium tremens
- Use of adjunct therapies is controversial as the focus should be on benzodiazepine treatment to prevent mortality, seizures and delirium tremens
- Plan ahead
 - Discharge plan considering harm reduction, 12-step program, abstinence



Benzodiazepines

Medication	Fixed schedule	Symptom-triggered
Day 1 Diazepam (Valium) Chlordiazepoxide (Librium) Lorazepam (Ativan)	10mg q6h 25-50mg q6h 2mg q8h	10mg q4h 25-50mg q4h 2mg q6h
Day 2 Diazepam (Valium) Chlordiazepoxide (Librium) Lorazepam (Ativan)	10mg q8h 25-50mg q8h 2mg q8h	10mg q6h 25-50mg q6h 2mg q6h
Day 3 Diazepam (Valium) Chlordiazepoxide (Librium) Lorazepam (Ativan)	10mg q12h 25-50mg q12h 1mg q8h	10mg q6h 25-50mg q6h 1mg q8h
Day 4 Diazepam (Valium) Chlordiazepoxide (Librium) Lorazepam (Ativan)	10mg at bedtime 25-50mg at bedtime 1mg q12h	10mg q12h 25-50mg q12h 1mg q12h
Day 5 Diazepam (Valium) Chlordiazepoxide (Librium) Lorazepam (Ativan)	10mg at bedtime 25-50mg at bedtime 1mg q12h	10mg q12h 25-50mg q12h 1mg q12h



Symptom triggered vs Front loading

Symptom triggered: CIWA-Ar ≥ 8

IV: diazepam 5 to 10 mg IV

Lorazepam 2 to 4 mg IV in patients with severe liver disease

Oral: chlordiazepoxide 25 to 100 mg orally

Oxazepam 10 to 30 mg orally in patients with severe liver disease

Front loading

IV: diazepam, 5 to 10 mg IV every 5 to 10 minutes, until the appropriate level of sedation is achieved

Lorazepam, 2 to 4 mg IV every 15 to 20 minutes

Oral: Chlordiazepoxide (Librium) 50 mg to 100 mg

Oxazepam (Serax) 15 mg to 30 mg 15 mg to 30 mg every 6 to 8 hours



Benzodiazepines with adequate nursing support

Symptom triggered

CIWA-Ar ≥ 8 : give diazepam 5 mg PO/IV, recheck in 4 hours

CIWA- Ar ≥ 15 : give diazepam 10 mg PO/IV, recheck in 2 hours

CIWA-Ar ≥ 20 : give diazepam 20 mg PO/IV, recheck in 1 hour

Front loading

Diazepam: 5 to 10 mg IV every 5 to 10 minutes, until the appropriate level of sedation is achieved.

Lorazepam: 2 to 4 mg IV every 15 to 20 minutes



Harm Reduction?

- What methods can be used to reduce harm in a person with alcohol use disorder?
- Which medications are commonly prescribed?



Harm reduction

AA and 12-step programs are more successful than motivational interviewing

Regular monthly follow ups increases rates of abstinence

Pharmacotherapy is underutilized in the treatment of AUD

Decreases relapse, decrease readmission rates, and decrease drinking days and drinking amount

- [Acamprosate](#)
- [Naltrexone](#)
- [Disulfiram](#)
- [Gabapentin](#)
- [Topiramate](#)

Wet houses

HARM REDUCTION 101



Harm reduction decreases the health risks of any activity without requiring you to stop the activity itself. Some common examples include bike helmets, seat belts, oven mitts, and “Don’t drink and drive” messages. Here is what you need to know about harm reduction and substance use:



1 IT WORKS!

Harm reduction is a well-researched, evidence-based approach shown to be effective in decreasing substance use related harms.



2 TO USE OR NOT TO USE

Harm reduction does not encourage substance use or force people to stop using; it is a non-judgmental approach that helps create opportunities for people to live healthier lives.



3 TWO SIDES TO EVERY COIN

Harm reduction accepts that people experience benefits as well as consequences when they use alcohol and other substances.



4 RIGHT HERE, RIGHT NOW

Harm reduction goals are about decreasing the more immediate harms and increasing the quality of life in the present. It is not concerned about striving unrealistically for a drug-free society.



5 THERE'S AN “I” IN WIN

Harm reduction respects each individual's goals and offers lots of choices. This allows people to focus on their most immediate need and have access to a broad range of options to help them stay safer and healthier. Small gains can lead to BIG successes!



algonquincollege.com/umbrellaproject



Naltrexone

Revia 50 mg daily

Prescribed to patients who want to reduce or abstain from alcohol

Lowers relapse rates

Lowers cravings

Decreases heavy drinking days

Harm reduction in patients who are trying to cut back)

Naltrexone + gabapentin is superior to naltrexone alone for sobriety



Acamprosate

Acamprosate 666 mg TID

Prescribed to patients who want to reduce or abstain from alcohol

Lowers relapse rates

Decreases cravings

Not as effective as naltrexone in head-to-head study in USA



Disulfiram

Antabuse 250-500 mg daily

Used if there is no response to acamprosate or naltrexone

Best if taken under supervision by support person

Do not give to persons who cannot tolerate disulfiram
reaction: liver disease, esophageal disease, heart failure, frail



Gabapentin or Topiramate

Decreases relapse rates

Not FDA approved for AUD

Considered second line

Can be started during withdrawal and continued after discharge



Adjunct therapies

Many experts do not like using adjunct therapies as they do not prevent seizures and may mask or decrease the scoring for the severity of the withdrawal

Only given if needed after adequate benzodiazepine therapy

Beta blockers for persistent hypertension and tachycardia: Atenolol 25 mg to 50 mg daily Metoprolol: 25 mg to 50 mg every 12 hours

Carbamazepine for additional control and to reduce cravings: 200 mg every 8 hours or 400 mg every 12 hours

Clonidine 0.2 mg for autonomic hyperactivity or anxiety

Gabapentin for additional control, reduces cravings and can be continued long term for MAT: 400 mg every 6 to 8 hours

